Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects

Ther Adv Neurol Disord. 2014 Sep;7(5):239-52. doi: 10.1177/1756285614546855.


A number of novel oral agents are now approved for use in relapsing multiple sclerosis (MS). Among these agents, teriflunomide has shown promise with respect to clinical efficacy and safety in relapsing MS patients. In this review we aim to clarify the role of teriflunomide in the context of current and emerging MS treatment options by summarizing relevant points on the use of teriflunomide in MS, with a discussion of teriflunomide's pharmacologic properties, pivotal clinical trials, and safety and tolerability.

Keywords: clinical trials; multiple sclerosis; review; teriflunomide.

Publication types

  • Review